Future of the Immuno-Oncology Drugs Market: Strategic Analysis and Forecast to 2034

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Immuno-Oncology Drugs Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market for immuno-oncology drugs has been expanding swiftly over the recent years. Expected to move from $94.16 billion in 2024 to hit $106.92 billion in 2025, the market predicts a compound annual growth rate (CAGR) of 13.6%. This substantial growth during the historic phase can be credited to the escalating number of cancer cases, robust economic advancements in developing markets, augmented spending on healthcare, and a rise in expenses for pharmaceutical research and development.

Immuno-Oncology Drugs Market Size Forecast: What's the Projected Valuation by 2029?
Strong expansion is anticipated for the immuno-oncology drugs market in the forthcoming years. The market is projected to reach a value of $153.16 billion in 2029, expanding at a compound annual growth rate (CAGR) of 9.4%. This growth during the prediction period can be credited to the rising investment in immuno-oncology, an increased emphasis on cancer treatment via immunotherapy drugs, and product innovations. Key trends to monitor in the forecast period are investments in the development of bespoke oncology drugs for individual patients, the advancement of next-generation biologics, emphasis on the creation of antibody-drug conjugates, investment in AI technologies to cut down R&D costs and shorten development time, investing in immune-oncology combination therapies to stimulate innovation and secure category leadership, and the application of car-t therapies to enhance innovations and attain category leadership.

View the full report here:
https://www.thebusinessresearchcompany.com/report/immuno-oncology-drug-global-market-report

What Are the Drivers Transforming the Immuno-Oncology Drugs Market?
The global increase in cancer incidences is expected to enhance the growth of the immuno-oncology drugs market. For example, the American Cancer Society predicted in January 2022, that an estimated 1.9 million new diagnoses of cancer, along with 609,360 cancer-related fatalities are projected for the US, which equates to roughly 1,670 casualties daily. The cancer types that are found most extensively globally, are lung, prostate, bowel, and female breast cancer, which together make up 43% of all fresh cases of cancer. These four major types of cancer account again, for 43% of the new cancer cases worldwide. Thus, the escalating levels of cancer incidents worldwide are projected to stimulate the demand for the immuno-oncology drugs market in the upcoming years.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3455&type=smp

What Long-Term Trends Will Define the Future of the Immuno-Oncology Drugs Market?
Leading corporations in the immuno-oncology drugs market are engaging in partnerships to innovate and promote a new checkpoint antibody that would improve cancer therapies. Strategic partnerships pave the way for innovation by enabling knowledge sharing across different disciplines, accelerating the creation of combination therapies, custom treatments, and innovative drug delivery systems. For example, in March 2023, German company BioNTech SE and US-based pharmaceutical firm OncoC4 Inc, collaborated to jointly develop and market a checkpoint antibody, particularly the anti-CTLA-4 monoclonal antibody candidate known as ONC-392. This collaboration is aimed at expanding treatment choices for various solid tumor indications.

Which Segments in the Immuno-Oncology Drugs Market Offer the Most Profit Potential?
The immuno-oncology drugs market covered in this report is segmented -

1) By Type: Immune Checkpoint Inhibitors, Immune System Modulators, Other Monoclonal Antibodies, Cancer Vaccines, Others
2) By Therapeutic Application: Melanoma, Lung Cancer, Blood Cancer, Renal Cell Carcinoma, Bladder Cancer, Other Therapeutic Application
3) By End-Users: Hospitals, Clinics, Ambulatory Surgical Centers, Others

Subsegments:
1) By Immune Checkpoint Inhibitors: PD-1 Inhibitors, PD-L1 Inhibitors, CTLA-4 Inhibitors
2) By Immune System Modulators: Cytokines, Interferons, Colony-Stimulating Factors
3) By Other Monoclonal Antibodies: Targeted Monoclonal Antibodies, Bispecific Antibodies
4) By Cancer Vaccines: Preventive Cancer Vaccines, Therapeutic Cancer Vaccines
5) By Others: Adoptive Cell Transfer Therapies, Oncolytic Virus Therapies

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=3455&type=smp

Which Firms Dominate the Immuno-Oncology Drugs Market by Market Share and Revenue in 2025?
Major companies operating in the immuno-oncology drugs market include F. Hoffmann-La Roche Ltd., Merck & Co., Bristol-Myers Squibb Company, Amgen Inc, Johnson & Johnson, AstraZeneca Plc, Eli Lilly and Company, Novartis International AG, Pfizer Inc., Sanofi S.A., Arlak Biotech, Apikos Pharma, Kolaz biotech, CStone Pharma, CARsgen Therapeutics, JW Therapeutics, BeiGene, Takeda Pharmaceuticals, Astellas Pharma Inc, Otsuka Pharmaceutical Co, Ltd, Legend Biotech Co, Zai Lab, Daiichi Pharmaceutical and Sankyo, AQVIDA GmbH, Baxter International Inc., GlaxoSmithKline plc, Affimed Therapeutics, Autolus Therapeutics, Cellectis, Celyad, GammaDelta Therapeutics, Immunocore, European Medical Center (EMC), Yauza Medical Center, Celon Pharma, Veropharm, Biocad, Selvita, OncoArendi Therapeutics Mabion, Fate Therapeutics, Forty-Seven, Arcus Biosciences, Gritstone Oncology, Rakuten Medical, Rubius Therapeutics, Allogene Therapeutics, Celgene Corporation, Bayer AG, Incyte Corporation, Recepta Biopharma, CSC Pharmaceuticals International, Blanver EN, Sandoz Brazil, Life Pharma, Julphar, NewBridge Pharmaceuticals, Eurolab

Which Regions Offer the Highest Growth Potential in the Immuno-Oncology Drugs Market?
North America was the largest region in the immuno-oncology drugs market in 2024. The regions covered in the immuno-oncology drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3455

This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas - +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.